These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38280299)
1. Optimization of oral entacapone administration in patients undergoing levodopa-carbidopa intestinal gel treatment. Miyaue N; Ito Y; Yamanishi Y; Tada S; Ando R; Yabe H; Nagai M J Neurol Sci; 2024 Feb; 457():122901. PubMed ID: 38280299 [TBL] [Abstract][Full Text] [Related]
2. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients. Müller T; Schlegel E; Zingler S; Thiede HM Cells; 2022 Apr; 11(9):. PubMed ID: 35563817 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of levodopa gel infusion in Parkinson's disease: effects of entacapone infusion and genetic polymorphism. Senek M; Nyholm D; Nielsen EI Sci Rep; 2020 Oct; 10(1):18057. PubMed ID: 33093598 [TBL] [Abstract][Full Text] [Related]
4. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease. Najib J Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off. Kuoppamäki M; Leinonen M; Poewe W J Neural Transm (Vienna); 2015 Dec; 122(12):1709-14. PubMed ID: 26347184 [TBL] [Abstract][Full Text] [Related]
6. Quality of life in early Parkinson's disease treated with levodopa/carbidopa/entacapone. Fung VS; Herawati L; Wan Y; ; Mov Disord; 2009 Jan; 24(1):25-31. PubMed ID: 18846551 [TBL] [Abstract][Full Text] [Related]
7. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309 [TBL] [Abstract][Full Text] [Related]
8. Jejunal Infusion of levodopa-carbidopa intestinal gel versus oral administration of levodopa-carbidopa tablets in japanese subjects with advanced Parkinson's disease: pharmacokinetics and pilot efficacy and safety. Othman AA; Chatamra K; Mohamed ME; Dutta S; Benesh J; Yanagawa M; Nagai M Clin Pharmacokinet; 2015 Sep; 54(9):975-84. PubMed ID: 25875940 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition. Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060 [TBL] [Abstract][Full Text] [Related]
10. Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease: A randomized crossover study. Senek M; Nielsen EI; Nyholm D Mov Disord; 2017 Feb; 32(2):283-286. PubMed ID: 27987231 [TBL] [Abstract][Full Text] [Related]
11. Levodopa-Entacapone-Carbidopa Intestinal Gel Treatment in Advanced Parkinson's Disease: A Single-Center Study of 30 Patients. Viljaharju V; Mertsalmi T; Pauls KAM; Koivu M; Eerola-Rautio J; Udd M; Pekkonen E Mov Disord Clin Pract; 2024 Feb; 11(2):159-165. PubMed ID: 38386490 [TBL] [Abstract][Full Text] [Related]
12. Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial. Nyholm D; Johansson A; Lennernäs H; Askmark H Eur J Neurol; 2012 Jun; 19(6):820-6. PubMed ID: 22136163 [TBL] [Abstract][Full Text] [Related]
13. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888 [TBL] [Abstract][Full Text] [Related]